Search Results - therapeutics

25 Results Sort By:
Selective PARP11 inhibitor for the treatment of cancer
​​​­Summary The current technology is a highly selective and potent inhibitor of PARP11 that could serve as an immuno-oncology therapeutic and enhance CAR-T cell therapies. Technology Overview Recent work identified PARP11 as a key component in driving tumor microenvironments (Nature Cancer, 2022), and suppression of PARP11 augmented the therapeutic...
Published: 9/19/2022   |   Inventor(s): Michael Cohen, Ilsa Kirby
Keywords(s): Therapeutics, Therapeutics - Cancer
Category(s): Therapeutics
Photoactivatable modulation of antibody binding
­ Summary The current technology involves a blocking construct that has the potential to increase antibody specificity and reduce unwanted off-target effects by modulating antibody activation in a manner that is predictable, reproducible and does not require genetic modification of the antibody sequence. Technology Overview Traditional antibodies...
Published: 1/4/2023   |   Inventor(s): Stuart Ibsen, Michael Brasino
Keywords(s): Diagnostics, Therapeutics
Category(s): Diagnostics, Therapeutics
Universal nanoprobes for imaging and treatment of cancer
Summary Medical imaging is currently incapable of detecting very small tumors and there is a need for new contrast agents that allow for earlier detection of cancers. The current technology is a self-assembled nanoprobe that specifically accumulates in a broad range of solid tumors to enable 1) high-resolution imaging for earlier cancer detection...
Published: 8/16/2022   |   Inventor(s): Adem Yildirim, Jared Fischer, Bruce Branchaud
Keywords(s): Diagnostics, Diagnostics - Cancer, Imaging, Therapeutics, Therapeutics - Cancer
Category(s): Diagnostics, Imaging, Therapeutics
SARS-CoV-2 single domain antibody (nanobody) for the treatment of COVID-19
Summary Oregon Health & Science University researchers have developed a highly potent SARS-CoV-2 neutralizing antibody that is effective against multiple variants and is highly stable, which could make it easy to store and transport. Technology Overview Nanobodies are functional single-domain antibodies from camelid species that offer several...
Published: 5/25/2022   |   Inventor(s): Fikadu Tafesse, Jules Weinstein, Timothy Bates
Keywords(s): COVID-19 Technologies, COVID-19 Technologies - Projects, Therapeutics, Therapeutics - Infectious Diseases
Category(s): Therapeutics
Development of a Novel Zebrafish Screening System and Identification of a Novel Protein That Induces Pancreatic Beta-Cell Proliferation
HEADLINE: Novel protein induces pancreatic beta cell proliferation, is ideal for diabetes treatment research Our scientists discovered a novel protein that offers a potential new avenue of research for labs developing drugs to treat diabetes. The newly-discovered BefA (β Cell Expansion Factor A) protein acts to increase total pancreatic...
Published: 5/2/2022   |   Inventor(s): Karen Guillemin, Jennifer Hampton
Keywords(s): Biochemistry, Biological Materials, Biotech, Therapeutics, Zebrafish
Category(s): Diagnostics, Therapeutics, Research Tools
Development of a Novel Zebrafish Screening System and Identification of a Novel Protein with Anti-Inflammatory Activity
HEADLINE: Novel protein with strong anti-inflammatory activity has been shown to effectively treat inflammatory bowel disease and prevent septic shock in zebrafish. University of Oregon scientists have discovered a novel protein with strong anti-inflammatory activity. The novel protein has been shown to effectively treat inflammatory bowel...
Published: 5/2/2022   |   Inventor(s): Karen Guillemin, Annah Rolig
Keywords(s): Biochemistry, Biological Materials, Biotech, Research Tools, Therapeutics, Zebrafish
Category(s): Research Tools, Therapeutics, Agricultural, Diagnostics
Methods of treating venetoclax-resistant acute myeloid leukemia
SummaryAcute myeloid leukemia (AML) is difficult to treat due to the genetic heterogeneity of the disorder and accompanying drug resistance observed in many patients. Oregon Health & Science University researchers have identified a new therapeutic approach to overcome venetoclax resistance and improve outcomes and prognoses for AML patients experiencing...
Published: 11/12/2021   |   Inventor(s): Jeffrey Tyner, Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Shannon McWeeney, Stephen (Steve) Kurtz, Christopher Eide, Ravindra Majeti
Keywords(s): Diagnostics, Diagnostics - Cancer, Therapeutics, Therapeutics - Cancer
Category(s): Diagnostics, Therapeutics
Mutation-specific treatment strategies for acute myeloid leukemia
Summary The implementation of targeted therapies for acute myeloid leukemia (AML) has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most mutational events. Oregon Health & Science University (OHSU) researchers have identified treatment strategies for a broad scope of AML...
Published: 10/3/2022   |   Inventor(s): Jeffrey Tyner, Cristina Tognon, Brian Druker, Daniel Bottomly, Beth Wilmot, Stephen (Steve) Kurtz, Samantha Savage, Nicola Long, Anna Reister Schultz, Elie Traer, Shannon McWeeney
Keywords(s): Diagnostics, Diagnostics - Cancer, Therapeutics, Therapeutics - Cancer
Category(s): Therapeutics, Diagnostics
Anti-cancer Compounds with Improved Cardiac Safety and Drug Resistance Profiles
SummaryTyrosine kinase inhibitors are effective targeted anti-cancer therapeutics, but currently available inhibitors have limitations due to drug resistance and cardiotoxic effects. Oregon Health & Science University researchers have developed a class of kinase inhibitors with an improved cardiovascular safety profile and the potential to overcome...
Published: 6/2/2022   |   Inventor(s): Sanjay Malhotra, Mallesh Pandrala, Dhanir Tailor, Mark Mercola, Arne Antoon Bruyneel
Keywords(s): Therapeutics, Therapeutics - Cancer
Category(s): Therapeutics
A first in class small molecule as a novel YB1 inhibitor.
SummaryThe development of resistance to chemotherapy treatment in solid tumors is associated with up-regulation of the DNA/RNA binding protein Y box binding protein 1 (YB-1) and a worsened prognosis for cancer patients. Oregon Health & Science University researchers have developed a first-in-class small molecule inhibitor of YB-1 that synergizes...
Published: 11/22/2021   |   Inventor(s): Sanjay Malhotra, Dhanir Tailor
Keywords(s): Therapeutics, Therapeutics - Cancer
Category(s): Therapeutics
1 2 3 
© 2023. All Rights Reserved. Powered by Inteum